Drugs News and Research

RSS

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions.

16 Nov 2013

New technique helps fight deadly pancreatic cancer using 2 types of nanoparticles

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new technique for fighting deadly and hard-to-treat pancreatic cancer that uses two different types of nanoparticles, the first type clearing a path into tumor cells for the second, which delivers chemotherapy drugs.

16 Nov 2013

Research could refine next generation of drugs to help treat dementia

A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.

15 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

The world should aim to have vaccines which reduce malaria cases by 75%, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 "Malaria Vaccine Technology Roadmap", launched today.

15 Nov 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.

15 Nov 2013

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014.

15 Nov 2013

Viewpoints: Despite website woes, administration should be given more time; health law credibility 'going up in smoke'

The enrollment numbers are in, and as expected, they are well short of projections. Around 106,000 enrolled in new plans during October - with approximately 27,000 coming from states where the federal government is running the exchange (with its extensive problems), and another 79,000 coming through the state exchanges. Republicans are gleefully pointing to the numbers as proof Obamacare needs to be scrapped entirely. That confirms two things we've long known to be true: the website is a disaster, and short term enrollment figures are a serious political problem for the White House and Democrats (Greg Sargent, 11/13).

15 Nov 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

15 Nov 2013

Researchers use new approach to parse roles of key mutated protein that causes familial AD

Researchers at the University of California, San Diego School of Medicine have used genetic engineering of human induced pluripotent stem cells to specifically and precisely parse the roles of a key mutated protein in causing familial Alzheimer's disease, discovering that simple loss-of-function does not contribute to the inherited form of the neurodegenerative disorder.

15 Nov 2013

Scientists discover new drug mechanism to reduce risk of infections

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.

15 Nov 2013

Copper intake via food and water can accelerate growth of tumors

Copper imbalances have been associated with a number of pathological conditions, including cancer. Publishing in PNAS scientists at EPFL have found that copper in drinking water - given at the maximum levels permitted in public water supplies - accelerated the growth of tumors in mice. On the other hand, reducing copper levels reduced tumor growth.

15 Nov 2013

Lower doses of antimalarial drug effective in reducing malaria transmission

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medicine researchers.

15 Nov 2013

$Research may explain why people who take bone-strengthening drugs are at-risk for atypical fractures$

Research may explain why people who take bone-strengthening drugs are at-risk for atypical fractures

Research with baboons at the Texas Biomedical Research Institute may help explain why some people who take bone-strengthening drugs like bisphosphonates are at-risk for atypical fractures in the long bones in their legs.

15 Nov 2013

Researchers exploit power of evolution to create new drug for use against heart disease

An international team of researchers led by the University of Leicester has "harnessed the power of evolution" to create a new drug for possible use against heart disease, inflammation and other illnesses.

15 Nov 2013

HIVMA's updated HIV care guidelines show doctors should focus on common health conditions

The HIV Medicine Association of the Infectious Diseases Society of America has updated its HIV care guidelines to reflect the fact that people with HIV are now living normal life spans, and their physicians need to focus on preventive care, including screening for high cholesterol, diabetes and osteoporosis.

15 Nov 2013

Medical researchers discover structure of potential drug target for rare genetic disease

Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.

15 Nov 2013

Malaria No More honors Hillary Rodham Clinton with Global Leadership Award

In an inspiring awards dinner Monday night, Malaria No More presented Former United States Secretary of State and Former Senator from New York Hillary Rodham Clinton with the Global Leadership Award.

15 Nov 2013

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

NeuroPace, Inc. today announced that the U.S. Food and Drug Administration has granted premarket approval for the NeuroPace RNS System, a treatment for adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs.

14 Nov 2013

Radiofrequency neurotomy may be successful alternative treatment for knee osteoarthritis

Chronic knee osteoarthritis is the deterioration of articular cartilage and is one of the most common diseases of aging. Millions of Americans have been diagnosed with knee osteoarthritis. OA often results in pain, restricted movement, sleep disturbance, and functional disability.

14 Nov 2013

Drugs News and Research

Intelliject to be recognized with George DiDomizio Industry Award

New technique helps fight deadly pancreatic cancer using 2 types of nanoparticles

Research could refine next generation of drugs to help treat dementia

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Viewpoints: Despite website woes, administration should be given more time; health law credibility 'going up in smoke'

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Researchers use new approach to parse roles of key mutated protein that causes familial AD

Scientists discover new drug mechanism to reduce risk of infections

Copper intake via food and water can accelerate growth of tumors

Lower doses of antimalarial drug effective in reducing malaria transmission

Research may explain why people who take bone-strengthening drugs are at-risk for atypical fractures

Researchers exploit power of evolution to create new drug for use against heart disease

HIVMA's updated HIV care guidelines show doctors should focus on common health conditions

Medical researchers discover structure of potential drug target for rare genetic disease

Malaria No More honors Hillary Rodham Clinton with Global Leadership Award

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

Radiofrequency neurotomy may be successful alternative treatment for knee osteoarthritis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News